مشخصات مقاله | |
انتشار | مقاله سال 2017 |
تعداد صفحات مقاله انگلیسی | 16 صفحه |
هزینه | دانلود مقاله انگلیسی رایگان میباشد. |
منتشر شده در | نشریه هینداوی |
نوع مقاله | ISI |
عنوان انگلیسی مقاله | Treatment of the Fluoroquinolone-Associated Disability: The Pathobiochemical Implications |
ترجمه عنوان مقاله | درمان ناتوانی فلوروکینولون وابسته: پیامدهای پاتوبیولوژیک |
فرمت مقاله انگلیسی | |
رشته های مرتبط | پزشکی و شیمی |
گرایش های مرتبط | شیمی دارویی |
مجله | پزشکی اکسیداسیون و طول عمر سلولی – Oxidative Medicine and Cellular Longevity |
دانشگاه | Adam Mickiewicz University in Poznań – Poland |
کد محصول | E5942 |
وضعیت ترجمه مقاله | ترجمه آماده این مقاله موجود نمیباشد. میتوانید از طریق دکمه پایین سفارش دهید. |
دانلود رایگان مقاله | دانلود رایگان مقاله انگلیسی |
سفارش ترجمه این مقاله | سفارش ترجمه این مقاله |
بخشی از متن مقاله: |
1. Long-Term Adverse
Reactions Caused by Fluoroquinolones Fluoroquinolones (FQ) belong to the group of broadspectrum antibiotics, effective for both gram-negative and gram-positive bacteria. The most frequently prescribed drugs are ciprofloxacin (CIP), norfloxacin (NOR), and levofloxacin (LEV). FQs employ their antibacterial effect by preventing bacterial DNA from unwinding and duplicating which takes place by inhibition of bacterial topoisomerase and gyrase. For the last three decades, FQs played an important role in treatment of serious bacterial infections, especially hospitalacquired infections. However, due to the possibility of serious side effects, these drugs are not currently first-line medicines and their use becomes more restrictive and limited. FQs should be reserved for those who do not have alternative treatment options. In 2016, the US Food and Drug Administration (FDA) updated warnings, using next “black box” for oral and injectable FQs. The authors showed that FQs, when used systemically, are associated with disabling and potentially permanent serious side effects. These side effects can involve the disruption of tendons, joins, muscles, nerves, nervous system disturbances, and even induction of type 2 diabetes. Due to the increasing number of reports about FQ toxicity and long-term complications, FDA has introduced significant restrictions on their use in recent years, particularly in children and in people aged 65 years. |